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ABSTRACT  
A major barrier to successful oral delivery of peptide and protein molecules is their inherent 
instability in the lumen of the gastrointestinal tract. The aim of this study was to determine the 
stability of 17 disparate peptide drugs (insulin, calcitonin, glucagon, secretin, somatostatin, 
desmopressin, oxytocin, [Arg8]- vasopressin, octreotide, ciclosporin, leuprolide, nafarelin, 
buserelin, histrelin, [D-Ser]4- gonadorelin, deslorelin, goserelin) in gastric and small intestinal 
fluids from both humans and pigs, and in simulated gastric and intestinal fluids. In human gastric 
fluid, the larger peptides including somatostatin, calcitonin, secretin, glucagon and insulin were 
metabolized rapidly, whereas the smaller peptides showed good stability. In human small 
intestinal fluid, however, both small and large peptides degraded rapidly with the exception of 
the cyclic peptide ciclosporin and the disulfide-bridge containing peptides octreotide and 
desmopressin, which showed good stability. From the investigations in simulated gastric and 
intestinal fluids without their respective enzymes pepsin and pancreatin, it was established that 
the pH was not responsible for peptide degradation. The stability of peptides in both simulated 
gastric fluid and pig gastric fluid correlated well with stability in human gastric fluid. However it 
was not possible to establish such a correlation with the small intestinal fluids because of the 
rapid rate of peptide degradation. This work has identified the molecular features in the structure 
of a wide range of peptides that influence their stability in the environment of the gastrointestinal 
tract, which in turn will allow for better selection of peptide candidates for oral delivery. 
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INTRODUCTION 
The increasingly widespread use of peptides and proteins as therapeutic drugs is rapidly 
expanding in diverse fields such as neurology, oncology, endocrinology, haematology, as well 
as in the treatment of inflammatory diseases. Coupled with recent advances in molecular 
biology and biotechnology, this has led to the synthesis of several peptide and protein 
molecules which offer the advantages of high activity, high specificity, low toxicity and minimal 
non-specific or drug-drug interactions. Somewhat inevitably, however, these drugs are also not 
without their shortcomings: The vast majority of currently marketed peptide drugs are delivered 
parenterally on account of stability issues; a route often unacceptable to the patient due to 
issues of pain and discomfort with administration, and which frequently leads to low patient 
compliance. Equally, there is also the associated issue of high systemic bioavailability and the 
risk of potentially severe side-effects with the intravenous route, including hypersensitivity 
responses. Various non-parenteral routes for the systemic delivery of peptide drugs have been 
so far investigated, including transdermal, nasal, buccal and pulmonary delivery, which have 
been met with some success in achieving therapeutic goals.1-4 The oral route is another 
increasingly-investigated alternative, given that it offers advantages in terms of ease of 
administration, lower manufacturing costs and increased patient compliance. To date, however, 
there are currently only five marketed orally delivered peptide and protein drugs available; 
desmopressin, ciclosporin, vancomycin, linaclotide and pancreatin. These molecules are orally 
available due to either the low systemic dose required (desmopressin),5 their high lipophilicity 
(ciclosporin),6 or because they are targeted for local, intestinal delivery (vancomycin, linaclotide 
and pancreatin).7, 8  
 
The two major barriers to effective oral peptide drug delivery include the instability of peptides in 
the gastrointestinal (GI) tract, and erratic absorption across the intestinal membrane into the 
systemic circulation. In terms of luminal stability, the highly acidic condition of the stomach is 
believed to be responsible for degradation of peptide drugs through destabilization of the three-
dimensional structural folding by interference with ionic and hydrogen bonding.9 Moreover the 
gastric-secreted enzyme pepsin and the intestinally-secreted enzymes trypsin, chymotrypsin, 
elastase and brush-border membrane-bound enzymes carboxypeptidases A and B cause 
hydrolysis of specific bonds, leading to peptide degradation and loss of structure and activity.9, 10  
 
The stability of peptides with GI enzymes and fluids have been assessed previously, but these 
studies have typically involved investigating only 1 or 2 peptide drugs, making it difficult to 
compare across studies due to variations in experimental conditions, biological fluids and 
analytical techniques. For instance, studies have included desmopressin stability in the 
presence of gastrointestinal enzymes,11 oxytocin and Arg-vasopressin in human stomach and 
small intestinal fluids,12 and insulin in pig gastric and intestinal luminal fluids.13 It would be of 
use, therefore, to assess the intestinal stability of a wider range of peptide drugs using the same 
biological fluids and analytical techniques within the same study in order to allow accurate 
comparisons to be made. This would enable the identification of those structural features that 
influence gastric and intestinal stability, allow for better selection of oral delivery candidates, and 
determine suitable formulation strategies.  
 
The aim of this study was to evaluate the stability of 17 disparate peptide drugs in human 
gastric (HGF) and small intestinal fluids (HIF), pig gastric (PGF) and small intestinal fluids (PIF) 
and simulated gastric (SGF) and intestinal fluids (SIF). The drugs display different physical and 
chemical properties and were selected to understand structural influences on gastric and 
intestinal stability. A schematic representation of the peptides along with their physicochemical 
properties is shown in Table 1. The molecules can be separated into three groups; a) small 
peptides with fewer than 12 amino acids and a partial or complete cyclic structure 
(desmopressin, oxytocin, Arg-vasopressin, octreotide and ciclosporin), b) small and linear 
peptides with fewer than 12 amino acids (nafarelin, buserelin, goserelin, histrelin, leuprolide, [D-
Ser]4-Gonadorelin and deslorelin) and c) large peptides with more than 12 amino acids 
(somatostatin, calcitonin, glucagon, secretin and insulin). This is the first study to 
comprehensively evaluate the gastrointestinal stability of a large number of peptides, and the 
data from the study will be useful in the selection of peptide candidate for oral peptide delivery. 
 
 
 
 Peptides 
 
Molecular 
weight 
 
No. of 
amino 
acids 
 
Isoelectric 
point 
 
Log P 
 
No. of H bond 
acceptors 
 
No. of H 
bond 
donors 
 
No. of Freely 
rotating 
bonds 
 
Polar Surface 
area 
Small Cyclic Peptides         
Ciclosporin 1202.6 11 4.70 3.64 23 5 16 278.80 
Oxytocin 1007 9 8.57 -5.00 24 16 19 399.53 
Vasopressin 1060.2 9 9.75 -6.77 25 18 22 425.55 
Desmopressin 1128.3 9 10.22 -6.13 26 18 20 435.41 
Octreotide 1019.2 8 10.97 -1.69 20 15 22 329.32 
Small Linear Peptides          
[D-Ser]
4
 Gonadorelin 1182.2 10 10.19 -6.26 30 19 33 471.73 
Nafarelin 1322.4 10 10.15 -2.97 33 22 35 469.23 
Histrelin 1323.5 9 9.95 -2.41 30 17 36 443.96 
Buserelin 1299.4 9 10.17 -3.35 29 17 35 437.87 
Leuprolide 1209.4 9 10.07 -2.75 28 17 34 428.64 
Goserelin 1269.4 10 9.72 -5.11 32 20 35 492.99 
Deslorelin 1282.4 9 9.96 -2.44 29 18 34 439.03 
Large peptides         
Somatostatin 1638.1 14 10.20 -8.50 37 26 32 610.33 
Calcitonin 3432 32 10.14 -28.49 54 52 98 1508.91 
Table 1 Physical properties of peptide molecules calculated by ChemSpider using the ACD/PhysChem Suite and software ChemAxon or 
unless referenced otherwise 
Glucagon 3485 29 8.20 -26.70 92 63 124 1580.71 
Secretin 3039 36 10.68 -24.89 47 52 109 1401.22 
Insulin 5809 51 5.40
14
 - 88 89 166 2450 
MATERIALS AND METHODS 
Materials 
Oxytocin acetate, buserelin acetate, goserelin acetate, nafarelin acetate, desmopressin acetate, 
leuprolide acetate, histrelin, [D-Ser]
4
-Gonadorelin, human recombinant insulin and [Arg
8
]- 
vasopressin acetate were obtained from Sigma-Aldrich, UK. Octreotide, deslorelin, somatostatin, 
glucagon, secretin and salmon calcitonin were purchased from Oxford Expression Technologies, 
UK. Ciclosporin was sourced from Abcam plc, UK. Trifluoroacetic acid, tween 80, pepsin from 
porcine gastric mucosa, 469 units/mg solid, pancreatin from porcine pancreas, activity at least 3 
times more than USP specifications were obtained from Sigma-Aldrich, UK. All other chemicals 
and solvents were of analytical reagent grade and used without further purification. All the salts 
were obtained from standard commercial sources. 
 
Sourcing and preparation of gastrointestinal fluids 
Human gastric fluid (HGF) and human intestinal fluid (HIF) 
HGF and HIF were provided by AstraZeneca, Sweden, through the University of Uppsala, 
Sweden. The sampling of fluids from the stomach and upper jejunum was achieved using an 
intestinal intubation device via the Loc-I-Gut® procedure.15, 16 The pH of the HGF and HIF was 
1.8 and 7.6 respectively. 
 
Pig gastric fluid (PGF) and pig intestinal fluid (PIF) 
Pig gastrointestinal tracts were obtained from three cross-breed of large white and landrace pigs 
(95-110 kg, 6 months old) at a meat factory (Cheale Meats, Essex, UK). The gastrointestinal 
tracts from pigs were then dissected to collect the fluid from the stomach and upper small 
intestine (duodenum and jejunum). The fluid was collected within 5 hours at 4⁰C after sacrifice 
of the pigs and immediately stored at -80⁰C. The fluid was centrifuged at 10,000 rpm for 10 
minutes, and the supernatants were used in the stability studies. The pH of the gastric and small 
intestinal supernatants was 3.4 ± 0.4 and 6.6 ± 0.2 respectively. 
 
Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) 
SGF was prepared according to USP specifications (Test Solutions, United States 
Pharmacopeia 35, NF 30, 2012). 0.2 g of sodium chloride was added to a 100 ml flask and 
dissolved in 50 ml water. 0.7 ml of 10 M HCl was added to adjust the pH of the solution to 1.2. 
To this, 0.32 g of pepsin was added and dissolved with gentle shaking, and the volume made up 
to 100 ml with water. Pepsin was added only after the pH was adjusted to 1.2. SIF was 
prepared according to USP specifications (Test Solutions, United States Pharmacopeia 35, NF 
30, 2012). 0.68 g of monobasic potassium phosphate was dissolved in 25 ml water, then 7.7 ml 
of 0.2 N NaOH was added to adjust the pH to 6.8. To this, 1g of pancreatin was added and 
shaken gently until dissolved, and the volume adjusted to 100 ml with water. Pancreatin was 
added after adjusting the pH of the solution to 6.8 to avoid precipitation of the enzyme. 
 
Determination of protease activity of the small intestinal fluids 
A protease activity kit (Sigma Aldrich, USA) was used to investigate the protease activity of HIF, 
PIF and SIF. The protease activity kit contained casein labelled with fluorescein isothiocyanate 
(FITC) as the substrate, with an excitation/emission maxima of 485/520 nm. 20 µl of incubation 
buffer, 20 µl of FITC-casein substrate and 10 µl of test sample (SIF with pancreatin/PIF/HIF) 
were added to an eppendorf tube and incubated at 37⁰C for 2 hours. After incubation, 150 µl of 
trichloroacetic acid (TCA) was added to the solution. This was centrifuged, and the fluorescence 
of the supernatant was measured using a fluorometer (BMG LABTECH PheraStar, Germany). 
The protease activity was calculated using MARS data analysis software. One unit of activity 
was defined as the amount of protease needed to hydrolyze FITC casein to produce a 
fluorescence intensity equivalent to 1ng of trypsin hydrolyzed FITC-Casein per hour at 37 °C.  
 
Peptide stability studies 
A stock solution of glucagon was prepared in 0.01N HCl, while secretin and calcitonin were 
prepared in a 0.9% NaCl solution to obtain a concentration of 6.7 x 10-4 mM. Insulin stock 
solution was prepared in 0.001N HCl at a concentration of 3.4 x 10-4 mM. All other peptide drugs 
were prepared by dissolving the drug in 0.9% NaCl solution to obtain a concentration of 6.7 x 
10-4 mM.  
 
The peptide incubation studies were performed in a Gallenkamp® shaking incubator at 37⁰C and 
100 rpm for 120 minutes. Peptide drug stock solution (6.7 x 10-4 mM) was added to the GI fluids 
and the final concentration of each peptide drug, with the exception of insulin, was 3.4 x 10-5 
mM. For insulin, the stock solution (3.4 x 10-4 mM) was added to GI fluids to obtain a final 
concentration of 6.9 x 10-5 mM during incubation. The higher concentration of insulin was 
required due to the low limit of detection of insulin by high performance liquid chromatography 
(HPLC). All incubations were done in triplicates expect for the study in human fluids, which were 
done in duplicates.  
 
Samples (150µl) were withdrawn at frequent time intervals and added to ice-cold stop reagent 
(450µl), i.e. methanol for gastric fluids and 0.1N HCl for intestinal fluids, to inactivate the 
enzymes and allow quantitative determination of intact peptide remaining. For insulin, the 
sample was added to 0.002M NaOH and 0.01N HCl to inactivate the gastric and intestinal 
enzymes respectively. Initial experiments had confirmed that the stop reagent had no 
degradative effect on peptide drug stability. All the samples were centrifuged at 10,000 rpm 
(9600 g) for 10 minutes, and the supernatant was analysed quantitatively by HPLC.  
 
Chromatographic analysis was performed with a HPLC system (Agilent Technologies, 1260 
Infinity) equipped with pump (model G1311C), autosampler (model G1329B) and a diode-array 
UV detector (model G1314B). The different chromatographic parameters for the peptides are 
shown in Table 2. The calibration curves were linear in the range 1.7 x 10-6 mM to 3.4 x 10-5 mM 
for all peptides. The peptide peak could be separated from the peaks from degradation product 
and protein peaks from gastric and intestinal fluids. 
Table 2 HPLC parameters for quantitative analysis of peptide drugs 
 Somatostatin Glucagon Calcitonin Secretin Oxytocin Buserelin Desmopressin Goserelin Nafarelin 
Column Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Temperature 40⁰C 25⁰C 25⁰C 25⁰C 25⁰C 33⁰C 25⁰C 33⁰C 25⁰C 
Injection 
Volume 
50 µl 50 µl 50 µl 50 µl 50 µl 50 µl 50 µl 50 µl 50 µl 
Flow rate 
 
1 ml/min 1 ml/min 1 ml/min 1 ml/min 1 ml/min 1 ml/min 0.7 ml/min 1 ml/min 1 ml/min 
UV absorbance 
(nm) 
214 nm 220 nm 220 nm 210 nm 220 nm 214 nm 220 nm 214 nm 224 nm 
Mobile Phase Acetonitrile 
(ACN) : Water : 
Phosphoric acid 
(22:78:0.5) 
Time  ACN    Water 
(min)        (0.1%TFA) 
0         20%    80% 
6         39%    61% 
12      39%     61% 
14      20%     80% 
18      20%     80% 
Time  ACN  Water 
(min)    (0.1%TFA) 
0         10%    90% 
6         37%    63% 
12      37%     63% 
14      10%     90% 
18      10%     90% 
Acetonitrile : 
Water : 70% 
perchloric acid 
(37:63:0.5) 
Water 
(0.1%TFA) : 
Acetonitrile 
(83:17) 
Water 
(0.1%TFA) : 
Acetonitrile 
(77:23) 
Water 
(0.1%TFA) : 
Acetonitrile 
(83:17) 
Water 
(0.1%TFA) : 
Acetonitrile 
(78:22) 
Water 
(0.1%TFA) : 
Acetonitrile 
(73:27) 
  
 Histrelin Leuprolide [D-Ser]
4
-
Gonadorelin 
[Arg
8
]-
vasopressin 
Octreotide Deslorelin Ciclosporin Insulin 
Column Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Luna 5µ C18 
150x4.6 mm 
Phenomenex
®
 
Discovery 
300⁰A C18 
150 x 4.6mm 
Temperature 25⁰C 25⁰C 25⁰C 25⁰C 25⁰C 25⁰C 70⁰C 40⁰C 
Injection Volume 50 µl 50 µl 50 µl 50 µl 50 µl 50 µl 50 µl 20μl 
Flow rate 1 ml/min 0.6 ml/min 1 ml/min 1 ml/min 1 ml/min 1 ml/min 0.7 ml/min 1ml/min 
UV absorbance (nm) 210 nm 210 nm 214 nm 214 nm 220 nm 210 nm 210 nm 210nm 
Mobile Phase Water 
(0.1%TFA) : 
Acetonitrile 
(77:23) 
Water 
(0.1%TFA) : 
Acetonitrile 
(70:30) 
Water (0.1%TFA) 
: Acetonitrile 
(84:16) 
Water 
(0.1%TFA) : 
Acetonitrile 
(87:13) 
Water  
(0.1%TFA) : 
Acetonitrile 
(82:18) 
Water 
(0.1%TFA) : 
Acetonitrile 
(75:25) 
Water   (0.1%TFA) 
: Acetonitrile 
(80:20) 
Water   
(0.1% TFA): 
Acetonitrile 
(0.1% TFA) 
(30-60%) 
Data analysis 
All experiments were performed in the same batch of GI fluids to avoid inter-day variability, and 
the results are presented as mean ± standard deviation (SD). The half-life (t1/2) of peptides in GI 
fluids was calculated from their degradation profiles, by linear regression analysis assuming 
zero-order or first order degradation kinetics, using Origin 9 (OriginLab Corporation, MA, USA).  
 
RESULTS 
The stability of the peptides in human gastric fluid (HGF) is shown in Figure 1a. The stability of 
the peptides in pig gastric fluid (PGF) and simulated gastric fluid (SGF) with pepsin is shown in 
Figures 1b and 1c respectively. With the exception of [D-Ser]4-Gonadorelin, the small peptides 
were stable in all three gastric fluids. In contrast, the large peptides were rapidly degraded 
within 10 minutes. Somatostatin was the exception as it showed relatively high stability in all 
gastric fluids.  
 
The stability of the peptide drugs in human intestinal fluid (HIF) is shown in Figure 2a. The 
stability of the peptide drugs in PIF and SIF is shown in Figures 2b and 2c respectively. The 
large peptides as well as the small peptides buserelin, goserelin, deslorelin, histrelin and 
leuprolide degraded rapidly within 2-10 minutes in all three small intestinal fluids. The small 
peptides which did not follow this trend were nafarelin and [D-Ser]4-Gonadorelin which showed 
higher stability in PIF but rapid degradation HIF and SIF. Oxytocin showed uniform stability in all 
three small intestinal fluids, with complete degradation achieved after 30 minutes, while Arg-
vasopressin was more stable in SIF than HIF and PIF. The peptides octreotide and 
desmopressin also showed relatively higher stability, but stability was variable between the 
fluids with fastest degradation observed in HIF followed by PIF and SIF. Ciclosporin was stable 
in all three small intestinal fluids. 
 
Figure 1. Stability of peptide drugs in human gastric fluid (a), pig gastric fluid (b) and simulated 
gastric fluid with pepsin (c). Nafarelin (     ), Buserelin (      ), Goserelin (       ), Histrelin (     ), 
Leuprolide (     ), Gonadorelin (        ), Deslorelin (      ), Desmopressin (       ), Oxytocin (      ), 
Arg-Vasopressin (      ), Octreotide (       ), Somatostatin (      ), Calcitonin (       ), Glucagon 
(       ), Secretin (         ), Insulin (         ), Ciclosporin (       ). 
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Figure 2. Stability of peptide drugs in human small intestinal fluid (a), pig intestinal fluid (b) and 
simulated intestinal fluid with pancreatin (c). Nafarelin (     ), Buserelin (      ), Goserelin (       ), 
Histrelin (     ), Leuprolide (     ), Gonadorelin (        ), Deslorelin (      ), Desmopressin (       ), 
Oxytocin (      ), Arg-Vasopressin (      ), Octreotide (       ), Somatostatin (      ), Calcitonin (       ), 
Glucagon (       ), Secretin (         ), Insulin (         ), Ciclosporin (       ). 
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The stability of the peptides in SGF and SIF without their respective enzymes pepsin and 
pancreatin is shown in Figures 3 and 4 respectively. In both fluids, all peptides were stable with 
more than 80% drug recovery after 2 hours (with the exception of calcitonin in SIF without 
pancreatin), highlighting the dominant role of GI enzymes in the breakdown and cleavage of the 
peptide structure. 
 
 
Figure 3. Stability of peptide drugs in intestinal fluid with pancreatin. Each value represents 
mean ± S.D (n=3). Nafarelin (       ), Buserelin (       ), Goserelin (       ), Histrelin (      ), 
Leuprolide (      ), Gonadorelin (        ), Deslorelin (      ), Desmopressin (       ), Oxytocin (      ), 
Arg-Vasopressin (      ), Octreotide (       ), Somatostatin (      ), Calcitonin (       ), Glucagon 
(       ), Secretin (         ), Insulin (         ), Ciclosporin (       ). 
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 Figure 4. Stability of peptide drugs in simulated gastric fluid without pepsin enzyme. Each value 
represents mean ± S.D (n=3). Nafarelin (       ), Buserelin (      ), Goserelin (       ), Histrelin (      ), 
Leuprolide (     ), Gonadorelin (       ), Deslorelin (      ), Desmopressin (     ), Oxytocin (      ), 
Arg-Vasopressin (      ), Octreotide (       ), Somatostatin (      ), Calcitonin (       ), Glucagon 
(       ), Secretin (         ), Insulin (         ).  
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In order to further understand the role of protease enzymes in the degradation of peptides in 
gastric and small intestinal fluids, the protease activity of all these fluids was measured. The 
protease activity in SGF with pepsin, PGF and HGF was 14237 ± 3099, 6749 ± 2464 and 10072 
± 3157 units/ml respectively while the protease activity in SIF with pancreatin, PIF and HIF was 
49649 ± 2610, 30730 ± 5575, 50608 ± 3880 units/ml respectively. The half-lives of the peptide 
drugs in all three gastric and small intestinal fluids are shown in Table 2 and 3 respectively; the 
half-lives of large peptides could not be obtained due to rapid degradation within 2 minutes. 
Good correlations were observed for the stability of the peptides in SGF and HGF (R2 = 0.917), 
PGF and HGF (R2 = 0.932) and SGF and PGF (R2 = 0.917). This suggests the ability of SGF 
and PGF to be used as an in-vitro model to predict the stability of peptides in human stomach, 
as well as the usefulness of SGF to simulate pig gastric conditions. 
 
Table 2  
The half lives and % peptide remaining after 2 hours in HGF, PGF and SGF with pepsin.  
Peptide HGF PGF SGF 
Half life 
(mins) 
% Drug 
remaining 
after 2 hours 
Half life 
(mins) 
% Drug 
remaining 
after 2 hours 
Half life 
(mins) 
% Drug 
remaining 
after 2 hours 
Nafarelin 491 89 822 92 
 
357 83 
 Buserelin 424 85 
 
274 79 
 
324 81 
 Goserelin 385 85 
 
376 84 
 
322 81 
 Histrelin 363 84 
 
440 85 
 
661 89 
 Leuprolide 267 77 
 
300 80 
 
166 65 
 [D-Ser]
4
-Gonadorelin * 0 
 
46 0 
 
80 31 
 Deslorelin 294 81 
 
468 86 
 
195 69 
 Desmopressin 633 89 
 
~ 100 
 
~ 99 
 Oxytocin 405 84 
 
884 93 
 
~ 100 
 [Arg
8
]-vasopressin 468 86 
 
~ 96 
 
1093 94 
 Octreotide 1071 92 
 
~ 98 
 
761 92 
 Ciclosporin 1374 93 
 
667 89 
 
480 87 
 Somatostatin 58 0 
 
98 42 
 
49 0 
 Calcitonin 2.0 0 
 
4.6 0 
 
2.1 0 
 Glucagon * 0 
 
* 0 
 
1.2 0 
 Secretin * 0 
 
1.1 0 
 
* 0 
 Insulin * 0 
 
* 0 
 
* 0 
  
~ Stable,  >95% peptide recovery after 2 hours 
* Unable to calculate t1/2 due to very fast degradation within 2 minutes  
Table 3  
The half lives and % peptide remaining after 30 minutes in HIF, PIF and SIF with pancreatin.  
Peptide HIF PIF SIF 
Half life 
(mins) 
% Drug 
remaining 
after 30 mins 
Half life 
(mins) 
% Drug 
remaining 
after 30 mins 
Half life 
(mins) 
% Drug 
remaining 
after 30 mins 
Nafarelin * 0 14 21 0.5 0 
Buserelin * 0 1.4 0 * 0 
 Goserelin * 0 
 
0.9 0 
 
* 0 
 Histrelin 1.1 0 3.2 0 
 
* 0 
 Leuprolide * 0 1.0 0 
 
* 0 
 [D-Ser]
4
-Gonadorelin * 0 8.0 0 
 
* 0 
 Deslorelin * 0 
 
2.9 0 
 
* 0 
 Desmopressin 15 25 63 73 50 74 
Oxytocin 6.8 0 8.9 0 
 
3.2 0 
 [Arg
8
]-vasopressin * 0 
 
2.9 0 
 
30 48 
 Octreotide 15 22 554 95 163 86 
Ciclosporin ~ 99 ~ 98 499 87 
Somatostatin * 0 
 
2.4 0 
 
* 0 
Calcitonin * 0 
 
* 0 
 
* 0 
 Glucagon * 0 
 
* 0 
 
* 0 
 Secretin * 0 * 0 
 
* 0 
 Insulin * 0 
 
* 0 
 
* 0 
  
~ Stable,  >95% peptide recovery after 2 hours 
* Unable to calculate t1/2 due to very fast degradation within 2 minutes  
 
 
 
 
 
 DISCUSSION 
The high stability of peptides in SGF without pepsin and the degradation of peptides in SGF with 
pepsin established the negligible effect of pH and the importance of the enzyme in the 
degradation of peptides in gastric conditions. Pepsin specifically cleaves amino acids at L-Phe-, 
L-Met-, L-Leu-, and L-Trp, which are adjacent to a hydrophobic amino acid.17, 18 Therefore the 
high gastric stability of the small peptides oxytocin, Arg-vasopressin, desmopressin, goserelin, 
buserelin, nafarelin and histrelin can be linked to the absence of pepsin-susceptible peptide 
bonds. Additionally, the peptides oxytocin, vasopressin and desmopressin feature disulfide 
bridges between their Cys amino acids which partially cyclizes their structure and results in high 
resistance to pepsin cleavage and their subsequent stability in gastric fluids. These results are 
in line with previous studies showing the high stability of Arg-vasopressin and desmopressin in 
gastric fluid.11, 12 Interestingly, ciclosporin, octreotide, leuprolide and deslorelin which all contain 
pepsin-vulnerable peptide bonds were found to be stable in SGF with pepsin. However, the 
pepsin vulnerable amino acids at position 6 in leuprolide and deslorelin, and position 4 in 
octreotide, are in the D-confirmation which may render them more resistant to pepsin cleavage 
due to the enzyme’s specificity towards L-amino acids.19 [D-Ser]4-Gonadorelin was degraded in 
gastric fluids even though it does not possess pepsin vulnerable bonds. This might be due to 
the L-confirmation of [D-Ser]4-Gonadorelin amino acid at position 6 compared to the D-
confirmation in other LHRH analogues. It was reported that the D-amino acid at position 6 could 
stabilize the U-shaped conformation of LHRH analogues, which could improve the binding 
affinity.20 Previous study has showed an analogue of gonadorelin with D-Lys amino acid 
substitution at position 6 to be stable in simulated gastric fluids with pepsin with 80% intact drug 
remaining after 2 hours.21 This may indicate the importance of D-confirmation of amino acid at 
position 6 for the stability of LHRH analogues in gastric fluids. The faster degradation of large 
peptides in gastric fluids may be due to multiple factors such as the presence of high number of 
pepsin susceptible peptide bonds, high structural flexibility and a greater number of H bond 
acceptors/donors, producing a higher polar surface area enabling increased interaction with 
pepsin 8. 
Pancreatin contains the proteases trypsin, chymotrypsin and elastase which are largely 
responsible for intestinal breakdown of peptide molecules.9 The peptide molecules were found 
to be degraded at different rates in small intestinal fluids, even though they all contain protease 
susceptible peptide bonds. This might be attributed to the differences in their physicochemical 
properties, as well as the different protease activity of the small intestinal fluids used in the 
current study. Indeed, the measured protease activity of SIF and HIF was almost 2-fold higher 
than for PIF, which may explain the higher stability of peptides such as octreotide, 
desmopressin and leuprolide in PIF. The greater stability of oxytocin, desmopressin, octreotide 
and ciclosporin as compared to the linear peptides in SIF could be attributed to their partial or 
complete cyclic structure and resultant reduced flexibility, fewer H bond acceptors/donors and 
fewer freely rotating, thereby restricting protease digestion.22, 23 The superior stability of 
desmopressin over Arg-vasopressin may be due to the D-arginine substitution at residue 8 
which may have increased its resistance towards trypsin.24 The faster degradation of large 
peptides in small intestinal conditions could be attributed to similar reasons, as observed in 
gastric fluids. Similar findings have previously been reported with salmon calcitonin and insulin, 
which were shown to be vulnerable to digestion in SIF,25-27 rat GI fluids,28-30 and PIF.27 A much 
slower degradation of insulin was observed in another study in the presence of proteases, with 
complete drug loss achieved only after 1 hour.31 This highlights the significance of studying the 
stability of peptides under identical experimental conditions in biological fluids obtained from the 
same source, and using the same analytical techniques/instruments for analysis, to minimize 
the variability observed in the results obtained from different studies. 
Owing to the ethical limitations on access to human GI fluids, the need to develop a suitable in-
vitro system that can be used for prediction of biopharmaceutical drug stability in early-stage 
drug development would be beneficial. The current study has highlighted the use of simulated 
and pig GI fluids as an effective in-vitro tool to predict the stability of biopharmaceuticals in the 
human GI tract by mimicking the physiological conditions. Considering the correlation observed 
between the half-life of peptides in SGF and PGF compared to HGF, both models appear to 
effectively mimic the in-vitro stability in human gastric conditions. However, the half-life of some 
peptides in small intestinal fluids could not be determined due to the extremely rapid rate of 
degradation; hence the same correlation could not be achieved between the stability of peptides 
in small intestinal fluids. However, the degradation of peptides in PIF and SIF showed similar 
trends as that observed in HIF, highlighting their ability to be implemented as good surrogates to 
HIF.  
 
 
CONCLUSIONS 
The stability of proteins and peptides in gastrointestinal fluids is an inherent problem associated 
with the oral delivery of these biopharmaceuticals. In order to ascertain whether differences 
existed in terms of peptide stability relating to factors such as molecular weight and size as well 
as regional exposure to gut fluids, we investigated the stability of 17 peptide drugs in human, pig 
and simulated fluids. Peptide stability was shown to vary widely depending on the amino acid 
sequence and higher structures. Cyclisation due to disulfide bond linkages resulting in high 
rigidity and low flexibility appeared to provide resistance against enzymatic cleavage of 
susceptible peptide bonds. Larger peptides, however, were more vulnerable to enzymatic 
cleavage due to the higher number of enzyme susceptible peptide bonds, and high structural 
flexibility. SGF and PGF appeared to be reasonably good models for predicting peptide stability 
in the human stomach, as they both demonstrated good correlation in terms of peptide stability 
to HGF. Despite similarities in the trend in peptide degradation in both PIF and SIF compared to 
HIF, a correlation of the half-lives could not be obtained due to the rapid rate of degradation in 
this segment of the gut. The overall outcome of the work has made it possible to identify those 
features in the structure of the molecules that influence gastric and intestinal stability, allow for 
better selection of peptide candidates for oral delivery, and determine suitable formulation 
strategies for those molecules with inherent stability issues.  
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